Participant's eligibility

The inclusion criteria for the study are:

- 16*-55 years of age, woman or man
- Alport diagnosis history & genetic test results positive for Alport syndrome
- Mild to moderate loss of kidney function
- Increased albuminuria
- ACE, ARB or SGLT2i treatment allowed**

About ALPESTRIA-1

- This Phase 2 study will evaluate:
  1. the safety of Vonafexor in Alport syndrome
  2. the benefit of three dose levels of Vonafexor on renal function and biomarkers.
- The study aims at enrolling **20 patients** in US and EU (France, Germany and Spain)
- **All participants** will receive Vonafexor as oral tablets once daily for 24 weeks then stop the treatment for 12 weeks in the follow-up period. No placebo – all subjects will receive study drug.
- Assessments are a mix of **5 site visits, 4 home visits and 4 phone calls**, with urine and/or blood sampling

* 16 years of age for the US; 18 years of age for the EU countries
** ACEi: angiotensin converting enzyme inhibitor
  ARB: angiotensin receptor blocker
  SGLT2i: sodium-glucose cotransporter-2 inhibitor

For more info about the study:

Please visit: www.alportsyndrome.org
Once the study is registered: www.clinicaltrials.gov and www.clinicaltrialsregister.eu